Global Ankylosing Spondylitis (AS) Drugs Market is Expected to Grow Revenue up to USD 10.92 Billion By 2030 with a Growing CAGR of 9.05% | Infinium Global Research

Infinium Global Research unveils a comprehensive exploration of the global and regional Ankylosing Spondylitis (AS) Drugs Market, offering profound insights into the segments, trends, forecasts, and monetary values in their recent report. This comprehensive study empowers pharmaceutical stakeholders with invaluable insights into this dynamically growing market.

To Know More Request a Sample of this Report: https://www.infiniumglobalresearch.com/market-reports/sample-request/419

Market Insight:

The global ankylosing spondylitis drugs market, valued at USD 5.5 billion in 2022, is projected to escalate to USD 10.92 billion by 2030, exhibiting a remarkable CAGR of 9.05% during the forecast period from 2023 to 2030.

Market Dynamics:

The AS drugs market caters to the pharmaceutical sector focusing on therapies designed to manage and alleviate the symptoms of ankylosing spondylitis, a chronic inflammatory disease primarily impacting the spine and large joints. This market encompasses a spectrum of drugs including NSAIDs, DMARDs, biologics, and other therapies intended to alleviate pain, inflammation, and slow disease progression for AS patients. Key market players are consistently investing in research and development to introduce innovative treatments, thus driving the expansion of the AS drugs market as they strive to meet the evolving needs of AS patients.

Drivers and Growth Factors:

The market's growth is primarily propelled by advancements in medical biologics. Ongoing advancements in biologic therapies targeting the underlying mechanisms of ankylosing spondylitis have revolutionized the treatment landscape. These innovative drugs offer enhanced efficacy, reduced side effects, and better disease management, significantly contributing to market growth. Increased awareness among the population about AS and its treatment positively impacts market expansion by leading to earlier diagnoses and driving the demand for effective treatments. However, the high costs associated with drug development and rigorous regulatory processes might impede market growth. Yet, the expansion of the healthcare sector and the intensified focus on research and development present promising opportunities for the AS drugs market in the forthcoming years.

Regional Market Insights:

North America is anticipated to dominate the AS drugs market due to rising AS patient numbers, major players engaged in drug development, and the region's advanced healthcare infrastructure. Meanwhile, the Asia Pacific region is projected to experience the highest growth rate in the global AS market during the forecast period. The region's increase in AS incidence, particularly in developing nations like China and India, directly contributes to the expanding market. Additionally, favorable reimbursement policies in countries like India, China, and Japan support market growth by encouraging patients to seek and continue treatment.

Segmentation Insights:

The report delves into segments encompassing drug classes (NSAIDs, TNF inhibitors, immunosuppressive drugs, steroids, etc.) and distribution channels (hospital pharmacy, retail pharmacy, online pharmacy).

Key Players Profiled:

Leading industry players such as Pfizer Inc., Merck & Co., Inc., and AbbVie Inc. are profiled in the report, offering insights into their market strategies and positioning.

Enquire Here Get Customization & Check the Discount for the Report @ https://www.infiniumglobalresearch.com/market-reports/customization/419

Table of Content

Chapter 1. Preface

1.1. Report Description

1.2. Research Methods

1.3. Research Approaches

Chapter 2. Executive Summary

2.1. Ankylosing Spondylitis Drugs Market Highlights

2.2. Ankylosing Spondylitis Drugs Market Projection

2.3. Ankylosing Spondylitis Drugs Market Regional Highlights

Chapter 3. Global Ankylosing Spondylitis Drugs Market Overview

3.1. Introduction

3.2. Market Dynamics

3.2.1. Drivers

3.2.2. Restraints

3.2.3. Opportunities

3.3. Porter`s Five Forces Analysis

3.4. IGR-Growth Matrix Analysis

3.4.1. IGR-Growth Matrix Analysis by Drug Class

3.4.2. IGR-Growth Matrix Analysis by Distribution Channel

3.4.3. IGR-Growth Matrix Analysis by Region

3.5. Value Chain Analysis of Ankylosing Spondylitis Drugs Market

Chapter 4. Ankylosing Spondylitis Drugs Market Macro Indicator Analysis

Chapter 5. Company Profiles and Competitive Landscape

5.1. Competitive Landscape in the Global Ankylosing Spondylitis Drugs Market

5.2. Companies Profiles

5.2.1. Pfizer Inc.

5.2.2. Merck & Co., Inc.

5.2.3. Boehringer Ingelheim International GmbH

5.2.4. UCB S.A., Belgium

5.2.5. Gilead Sciences, Inc.

5.2.6. Johnson & Johnson Services, Inc.

5.2.7. AbbVie Inc.

5.2.8. Hetero

5.2.9. Zydus Lifesciences

5.2.10. Novartis AG

Chapter 6. Global Ankylosing Spondylitis Drugs Market by Drug Class

6.1. NSAIDs

6.2. TNF Inhibitors

6.3. Immunosuppressive Drugs

6.4. TNF Blockers

6.5. JAK Inhibitors

6.6. Steroids

6.7. Others

Chapter 7. Global Ankylosing Spondylitis Drugs Market by Distribution Channel

7.1. Hospital Pharmacy

7.2. Retail Pharmacy

7.3. Online Pharmacy

Chapter 8. Global Ankylosing Spondylitis Drugs Market by Region 2023-2030

8.1. North America

8.1.1. North America Ankylosing Spondylitis Drugs Market by Drug Class

8.1.2. North America Ankylosing Spondylitis Drugs Market by Distribution Channel

8.1.3. North America Ankylosing Spondylitis Drugs Market by Country

8.1.3.1. The U.S. Ankylosing Spondylitis Drugs Market

8.1.3.1.1. The U.S. Ankylosing Spondylitis Drugs Market by Drug Class

8.1.3.1.2. The U.S. Ankylosing Spondylitis Drugs Market by Distribution Channel

8.1.3.2. Canada Ankylosing Spondylitis Drugs Market

8.1.3.2.1. Canada Ankylosing Spondylitis Drugs Market by Drug Class

8.1.3.2.2. Canada Ankylosing Spondylitis Drugs Market by Distribution Channel

8.1.3.3. Mexico Ankylosing Spondylitis Drugs Market

8.1.3.3.1. Mexico Ankylosing Spondylitis Drugs Market by Drug Class

8.1.3.3.2. Mexico Ankylosing Spondylitis Drugs Market by Distribution Channel

8.2. Europe

8.2.1. Europe Ankylosing Spondylitis Drugs Market by Drug Class

8.2.2. Europe Ankylosing Spondylitis Drugs Market by Distribution Channel

8.2.3. Europe Ankylosing Spondylitis Drugs Market by Country

8.2.3.1. Germany Ankylosing Spondylitis Drugs Market

8.2.3.1.1. Germany Ankylosing Spondylitis Drugs Market by Drug Class

8.2.3.1.2. Germany Ankylosing Spondylitis Drugs Market by Distribution Channel

8.2.3.2. United Kingdom Ankylosing Spondylitis Drugs Market

8.2.3.2.1. United Kingdom Ankylosing Spondylitis Drugs Market by Drug Class

8.2.3.2.2. United Kingdom Ankylosing Spondylitis Drugs Market by Distribution Channel

8.2.3.3. France Ankylosing Spondylitis Drugs Market

8.2.3.3.1. France Ankylosing Spondylitis Drugs Market by Drug Class

8.2.3.3.2. France Ankylosing Spondylitis Drugs Market by Distribution Channel

8.2.3.4. Italy Ankylosing Spondylitis Drugs Market

8.2.3.4.1. Italy Ankylosing Spondylitis Drugs Market by Drug Class

8.2.3.4.2. Italy Ankylosing Spondylitis Drugs Market by Distribution Channel

8.2.3.5. Rest of Europe Ankylosing Spondylitis Drugs Market

8.2.3.5.1. Rest of Europe Ankylosing Spondylitis Drugs Market by Drug Class

8.2.3.5.2. Rest of Europe Ankylosing Spondylitis Drugs Market by Distribution Channel

8.3. Asia Pacific

8.3.1. Asia Pacific Ankylosing Spondylitis Drugs Market by Drug Class

8.3.2. Asia Pacific Ankylosing Spondylitis Drugs Market by Distribution Channel

8.3.3. Asia Pacific Ankylosing Spondylitis Drugs Market by Country

8.3.3.1. China Ankylosing Spondylitis Drugs Market

8.3.3.1.1. China Ankylosing Spondylitis Drugs Market by Drug Class

8.3.3.1.2. China Ankylosing Spondylitis Drugs Market by Distribution Channel

8.3.3.2. Japan Ankylosing Spondylitis Drugs Market

8.3.3.2.1. Japan Ankylosing Spondylitis Drugs Market by Drug Class

8.3.3.2.2. Japan Ankylosing Spondylitis Drugs Market by Distribution Channel

8.3.3.3. India Ankylosing Spondylitis Drugs Market

8.3.3.3.1. India Ankylosing Spondylitis Drugs Market by Drug Class

8.3.3.3.2. India Ankylosing Spondylitis Drugs Market by Distribution Channel

8.3.3.4. South Korea Ankylosing Spondylitis Drugs Market

8.3.3.4.1. South Korea Ankylosing Spondylitis Drugs Market by Drug Class

8.3.3.4.2. South Korea Ankylosing Spondylitis Drugs Market by Distribution Channel

8.3.3.5. Australia Ankylosing Spondylitis Drugs Market

8.3.3.5.1. Australia Ankylosing Spondylitis Drugs Market by Drug Class

8.3.3.5.2. Australia Ankylosing Spondylitis Drugs Market by Distribution Channel

8.3.3.6. Rest of Asia-Pacific Ankylosing Spondylitis Drugs Market

8.3.3.6.1. Rest of Asia-Pacific Ankylosing Spondylitis Drugs Market by Drug Class

8.3.3.6.2. Rest of Asia-Pacific Ankylosing Spondylitis Drugs Market by Distribution Channel

8.4. RoW

8.4.1. RoW Ankylosing Spondylitis Drugs Market by Drug Class

8.4.2. RoW Ankylosing Spondylitis Drugs Market by Distribution Channel

8.4.3. RoW Ankylosing Spondylitis Drugs Market by Sub-region

8.4.3.1. Latin America Ankylosing Spondylitis Drugs Market

8.4.3.1.1. Latin America Ankylosing Spondylitis Drugs Market by Drug Class

8.4.3.1.2. Latin America Ankylosing Spondylitis Drugs Market by Distribution Channel

8.4.3.2. Middle East Ankylosing Spondylitis Drugs Market

8.4.3.2.1. Middle East Ankylosing Spondylitis Drugs Market by Drug Class

8.4.3.2.2. Middle East Ankylosing Spondylitis Drugs Market by Distribution Channel

8.4.3.3. Africa Ankylosing Spondylitis Drugs Market

8.4.3.3.1. Africa Ankylosing Spondylitis Drugs Market by Drug Class

8.4.3.3.2. Africa Ankylosing Spondylitis Drugs Market by Distribution Channel

More Insights on this report, Speak to Our Analyst: https://www.infiniumglobalresearch.com/market-reports/enquiry/419

Reasons to Buy this Report:

=> Comprehensive analysis of global as well as regional markets of ankylosing spondylitis drugs.

=> Complete coverage of all the product types and application segments to analyze the trends, developments, and forecast of market size up to 2030.

=> Comprehensive analysis of the companies operating in this market. The company profile includes an analysis of the product portfolio, revenue, SWOT analysis, and the latest developments of the company.

=> Infinium Global Research- Growth Matrix presents an analysis of the product segments and geographies that market players should focus on to invest, consolidate, expand, and/or diversify.

2nd Floor, Ganadish Empire, Rahatani Chowk, Pimple Saudagar, Pimpri-Chinchwad, Maharashtra 411027

About Infinium Global Research:

Infinium Global Research is a business consulting and market research firm; a group of experts that caters to fulfilling business and market research needs of leading companies in various industry verticals and business segments. The company also serves government bodies, institutes, and non-profit/non-government organizations to meet their knowledge and information needs.

Through our information services and solutions, we assist our clients to improve their performance and assess the market conditions to achieve their organizational goals. Our team of experts and analysts are engaged in continuously monitoring and assessing the market conditions to provide knowledge support to our clients. To help our clients and to stay updated with the advances and inventions in technology, business processes, regulations, and the environment, Infinium often conducts regular meets with industry experts and opinion leaders. Our key opinion leaders are involved in monitoring and assessing the progress in the business environment, so as to offer the best opinion to our clients.

This release was published on openPR.